Kim Jung A, Choi Kyung Mook
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea.
Front Physiol. 2020 Sep 2;11:568800. doi: 10.3389/fphys.2020.568800. eCollection 2020.
With the increasing prevalence of obesity, obesity-related problems such as cardiometabolic disorders (CMD), are also rapidly increasing. To prevent and alleviate the progressive course of CMD, it is important to discover the pathophysiological mechanisms between obesity and CMD. Adipose tissue is now recognized as an active endocrine organ that releases adipokines. Adipokines play a pivotal role in chronic low-grade inflammation, oxidative stress, and impaired insulin signaling, contributing to metabolic derangement and leading to CMD. Recent studies have provided substantial evidence supporting the association between adipokines and CMD. In this review, we highlight the pathophysiological action of adipokines in CMD that includes metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular diseases. We focused on translational and clinical research of novel adipokines associated with metabolic and cardiovascular regulation. Exploration of the role of these adipokines connecting obesity and CMD may provide a perspective on adipokine-based therapeutic implications for CMD.
随着肥胖患病率的不断上升，与肥胖相关的问题，如心脏代谢紊乱（CMD），也在迅速增加。为了预防和缓解CMD的进展过程，发现肥胖与CMD之间的病理生理机制很重要。脂肪组织现在被认为是一个释放脂肪因子的活跃内分泌器官。脂肪因子在慢性低度炎症、氧化应激和胰岛素信号受损中起关键作用，导致代谢紊乱并引发CMD。最近的研究提供了大量证据支持脂肪因子与CMD之间的关联。在这篇综述中，我们重点介绍了脂肪因子在CMD中的病理生理作用，包括代谢综合征、2型糖尿病、非酒精性脂肪性肝病和心血管疾病。我们专注于与代谢和心血管调节相关的新型脂肪因子的转化和临床研究。探索这些连接肥胖与CMD的脂肪因子的作用，可能为基于脂肪因子的CMD治疗意义提供一个视角。
